A Payer Bonus, Two Skeptical Physicians, and One Pharmacist FTE
You lead pharmacy services across a four-site federally qualified health center. Administration has asked you to "improve hypertension control" because a payer bonus tied to BP below 140/90 is at risk: the center's control rate is 58% against a 70% target across 2,400 adults with hypertension. You have 1.0 FTE clinical pharmacist, 0.5 FTE technician, and a collaborative practice agreement permitting initiation and titration for hypertension and diabetes - but not for anticoagulation or heart failure. Two physicians are openly skeptical of the service; one has asked you to "just handle refills" for a panel of 200 patients who have not been seen in over a year. Front desk currently books pharmacist visits only on Tuesdays.
1. How do you prioritize the first 90 days, and what data do you use?
Read the worked answer
Start by refusing to treat 2,400 patients as one problem. Stratify the registry into three actionable tiers:
- Uncontrolled and dangerous - BP ≥160/100 or ≥140/90 with no visit in 12 months. These patients drive both outcomes and events; they are also the ones a refill-only model would miss entirely.
- Uncontrolled but engaged - seen recently, on 1–2 agents, therapeutic inertia is the issue. These respond fastest to protocol-driven titration.
- Controlled - leave alone; do not consume pharmacist capacity here.
Highest-yield first moves: open pharmacist scheduling beyond Tuesday (a one-day-per-week clinic structurally cannot move a 2,400-patient measure), build a registry worklist with the technician pulling the most recent BP, med list, and labs, and use the CPA to titrate on the tier-2 patients with remote BP readings.
Metrics to report monthly: percent with BP <140/90 (overall and by site and by language), number of medication titrations per 100 visits, time from uncontrolled reading to next touch, and visit no-show rate. Report tier-1 outreach completion separately - it will look slow and needs its own narrative.
2. How do you respond to the physician who wants you to "just handle refills" for 200 unseen patients?
Read the worked answer
Say yes to the underlying problem and no to the specific request - and be explicit about the difference.
Why the request cannot be accepted as stated: refill authorization without an assessment is not a pharmacist service, it is a liability transfer. You cannot titrate or take responsibility for a BP you have never measured in a patient with no labs, and doing so would also breach the CPA, which requires an assessment and documentation for initiation and titration. Accepting it would also confirm the skeptics' belief that the pharmacist is a task absorber rather than a clinician.
What to offer instead: take the 200-patient list and convert it into a protocolized outreach panel - chart review, home BP cuff issued, a scheduled 20-minute pharmacist visit (in person or telehealth), labs ordered as needed, and titration under the CPA with the referring physician notified of every change. Offer to co-manage rather than to take over. Share the list back with the physician after 30 days so they see what was found (undiagnosed CKD, NSAID use, nonadherence) - that converts a skeptic faster than any argument.
Ask for one thing in return: the physician's agreement to co-sign the protocol and be named as a collaborator on the CPA renewal.
3. What operational and financial infrastructure does the service need to be sustainable after the bonus year?
Read the worked answer
A measure-driven service collapses when the measure changes. Build durability on four legs:
1. Scope. Negotiate CPA renewal to cover anticoagulation and heart failure guideline-directed therapy - the two areas where pharmacist management has the clearest event-reduction case and where the current agreement leaves obvious gaps.
2. Billing and staffing. Map visit types to billable services (incident-to physician visits in this setting, chronic care management, transitional care management, annual wellness visit support). Model technician time explicitly: the technician, not the pharmacist, should be doing registry pulls, outreach calls, and scheduling - that is the only way 1.0 FTE pharmacist generates enough visits.
3. Access. Spread scheduling across sites and days; a single Tuesday clinic will keep no-show rates high and access low.
4. Governance. Establish a monthly review with the medical director and the two skeptics, reporting the same four metrics every month. Present a run chart, not a one-time comparison - clinicians discount before/after numbers but respect a trend line.
Set a decision point at 6 months: if titration volume and control rate are not moving, the problem is workflow, not the model, and the CPA and scheduling need revisiting before asking for more FTE.